April 27
@
12:00 PM
–
1:00 PM
Preclinical nuclear medicine and magnetic resonance imaging for theranostic radiopharmaceutical development
Paul Ellison, PhD
Assistant Professor, Medical Physics
School of Medicine and Public Health
University of Wisconsin-Madison
Abstract:
The development of radiopharmaceuticals for use in nuclear medicine for the diagnosis and treatment of disease is a highly interdisciplinary field that integrates elements of engineering, materials science, physics, chemistry, and biology. It requires the use of a wide variety of specialty equipment, like particle accelerators, automated radiochemical synthesizers, and imaging systems, such as positron emission tomography (SPECT) or single photon emission computed tomography (SPECT) that provide biochemical information-rich spatial images, which are often paired with a second modality, such as x-ray computed tomography (CT) or magnetic resonance imaging (MRI) to provide accurate anatomical references. In this presentation, Dr. Ellison will discuss recent efforts to develop novel theranostic small molecule radiopharmaceuticals for PET imaging and radiopharmaceutical therapy of glioblastoma through targeting system xC–, a cell surface antiporter that exchanges cystine and glutamate as a key part of the cellular antioxidant defense system. Using modern chemically versatile halodeborylation chemistries, Dr. Ellison’s laboratory has prepared homologously matched radiopharmaceuticals that emit a variety of medically useful radiations, including positrons (18F, 77Br) and photons (131I) for imaging and Auger electrons (77Br) and beta particles (131I) for therapy. Comparative biology studies of this family of compounds utilize the gamut of preclinical imaging technologies, including PET, SPECT, CT, and MRI.
Print PDF